• Je něco špatně v tomto záznamu ?

Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications

F. Darzentas, M. Szczepanowski, M. Kotrová, A. Hartmann, T. Beder, N. Gökbuget, S. Schwartz, L. Bastian, CD. Baldus, K. Pál, N. Darzentas, M. Brüggemann

. 2023 ; 14 (-) : 1125017. [pub] 20230418

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011753

INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of VH replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic details of oligoclonal composition of the leukemia at diagnosis, clonal evolution during follow-up, and clonal distribution in different hematopoietic compartments. METHODS: Utilizing high-throughput sequencing assays and bespoke bioinformatics we identified BCP-ALL-derived clonally-related IGH sequences by their shared 'DNJ-stem'. RESULTS: We introduce the concept of 'marker DNJ-stem' to cover the entirety of, even lowly abundant, clonally-related family members. In a cohort of 280 adult patients with BCP-ALL, IGH clonal evolution at diagnosis was identified in one-third of patients. The phenomenon was linked to contemporaneous recombinant and editing activity driven by aberrant ongoing DH/VH-DJH recombination and VH replacement, and we share insights and examples for both. Furthermore, in a subset of 167 patients with molecular subtype allocation, high prevalence and high degree of clonal evolution driven by ongoing DH/VH-DJH recombination were associated with the presence of KMT2A gene rearrangements, while VH replacements occurred more frequently in Ph-like and DUX4 BCP-ALL. Analysis of 46 matched diagnostic bone marrow and peripheral blood samples showed a comparable clonal and clonotypic distribution in both hematopoietic compartments, but the clonotypic composition markedly changed in longitudinal follow-up analysis in select cases. Thus, finally, we present cases where the specific dynamics of clonal evolution have implications for both the initial marker identification and the MRD monitoring in follow-up samples. DISCUSSION: Consequently, we suggest to follow the marker DNJ-stem (capturing all family members) rather than specific clonotypes as the MRD target, as well as to follow both VDJH and DJH family members since their respective kinetics are not always parallel. Our study further highlights the intricacy, importance, and present and future challenges of IGH clonal evolution in BCP-ALL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011753
003      
CZ-PrNML
005      
20230801133319.0
007      
ta
008      
230718s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2023.1125017 $2 doi
035    __
$a (PubMed)37143651
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Darzentas, Franziska $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
245    10
$a Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications / $c F. Darzentas, M. Szczepanowski, M. Kotrová, A. Hartmann, T. Beder, N. Gökbuget, S. Schwartz, L. Bastian, CD. Baldus, K. Pál, N. Darzentas, M. Brüggemann
520    9_
$a INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of VH replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic details of oligoclonal composition of the leukemia at diagnosis, clonal evolution during follow-up, and clonal distribution in different hematopoietic compartments. METHODS: Utilizing high-throughput sequencing assays and bespoke bioinformatics we identified BCP-ALL-derived clonally-related IGH sequences by their shared 'DNJ-stem'. RESULTS: We introduce the concept of 'marker DNJ-stem' to cover the entirety of, even lowly abundant, clonally-related family members. In a cohort of 280 adult patients with BCP-ALL, IGH clonal evolution at diagnosis was identified in one-third of patients. The phenomenon was linked to contemporaneous recombinant and editing activity driven by aberrant ongoing DH/VH-DJH recombination and VH replacement, and we share insights and examples for both. Furthermore, in a subset of 167 patients with molecular subtype allocation, high prevalence and high degree of clonal evolution driven by ongoing DH/VH-DJH recombination were associated with the presence of KMT2A gene rearrangements, while VH replacements occurred more frequently in Ph-like and DUX4 BCP-ALL. Analysis of 46 matched diagnostic bone marrow and peripheral blood samples showed a comparable clonal and clonotypic distribution in both hematopoietic compartments, but the clonotypic composition markedly changed in longitudinal follow-up analysis in select cases. Thus, finally, we present cases where the specific dynamics of clonal evolution have implications for both the initial marker identification and the MRD monitoring in follow-up samples. DISCUSSION: Consequently, we suggest to follow the marker DNJ-stem (capturing all family members) rather than specific clonotypes as the MRD target, as well as to follow both VDJH and DJH family members since their respective kinetics are not always parallel. Our study further highlights the intricacy, importance, and present and future challenges of IGH clonal evolution in BCP-ALL.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a polymerázová řetězová reakce $7 D016133
650    12
$a pre-B-buněčná leukemie $x diagnóza $x genetika $7 D015452
650    _2
$a geny pro imunoglobuliny $7 D005803
650    12
$a Burkittův lymfom $x genetika $7 D002051
650    _2
$a kostní dřeň $x patologie $7 D001853
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Szczepanowski, Monika $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Kotrová, Michaela $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Hartmann, Alina $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany $u University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany $u Clinical Research Unit "CATCH-ALL" (KFO 5010/1), funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Bonn, Germany
700    1_
$a Beder, Thomas $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany $u University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Gökbuget, Nicola $u Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt/M, Germany
700    1_
$a Schwartz, Stefan $u Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany $u German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Bastian, Lorenz $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany $u University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany $u Clinical Research Unit "CATCH-ALL" (KFO 5010/1), funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Bonn, Germany
700    1_
$a Baldus, Claudia Dorothea $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany $u University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany $u Clinical Research Unit "CATCH-ALL" (KFO 5010/1), funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Bonn, Germany
700    1_
$a Pál, Karol $u Central European Institute of Technology, Masaryk University, Brno, Czechia
700    1_
$a Darzentas, Nikos $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Brüggemann, Monika $u Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany $u University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany $u Clinical Research Unit "CATCH-ALL" (KFO 5010/1), funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Bonn, Germany
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 14, č. - (2023), s. 1125017
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37143651 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133316 $b ABA008
999    __
$a ok $b bmc $g 1963913 $s 1198018
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1125017 $e 20230418 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace